CD137 ligand activated microglia induces oligodendrocyte apoptosis via reactive oxygen species

Journal of Neuroinflammation

Herbert Schwarz³  Eng-Ang Ling¹  Stephan Gasser³  J Ludovic Croxford²  Julia M Martínez Gómez²  Yee Andy Yeo³ 

[1] Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Blk MD10, 4 Medical Drive, Singapore, 117597, Singapore;Immunology Programme, National University of Singapore, Singapore, Singapore;NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore, Singapore

关键词: Multiple sclerosis;    Experimental autoimmune encephalomyelitis;    CD137;    Apoptosis;    Oligodendrocyte;    Microglia;   

Others  :  1160373
DOI  :  10.1186/1742-2094-9-173

 received in 2012-02-21, accepted in 2012-07-16,  发布年份 2012

【 摘 要 】

CD137 (4-1BB, TNFRSF9), a member of the tumor necrosis factor (TNF) receptor family, is a potent T cell co-stimulatory molecule. CD137 ligand (CD137L) is expressed by antigen presenting cells (APC) as a transmembrane protein and transmits activating signals into APC. In this study we investigated the effects of CD137L signaling in microglia, the resident APC in the central nervous system. In vitro, the murine microglia cell lines BV-2 and N9, as well as primary murine microglia responded with activation as evidenced by adherence and secretion of proinflammatory cytokines, MMP-9, and soluble intercellular adhesion molecule (ICAM). CD137L signaling is also important for microglia activation in vivo, since CD137L-deficient mice exhibited profoundly less microglia activation during experimental autoimmune encephalomyelitis (EAE) which is a well-established murine model for neuroinflammation and human multiple sclerosis (MS). Also CD137 is expressed in the CNS of mice during EAE. Activated microglia has been reported to mediate the destruction of axonal myelin sheaths and cause the death of oligodendrocytes, the main pathogenic mechanisms in EAE and MS. Corresponding to the lower microglia activation there were also fewer apoptotic oligodendrocytes in the CNS of CD137L-deficient mice. In vitro co-culture confirmed that CD137L-activated microglia induces apoptosis in oligodendrocytes, and identified reactive oxygen species as the mechanism of apoptosis induction. These data demonstrate activating effects of CD137L signaling to microglia, and show for the first time that the CD137 receptor/ligand system may be a mediator of neuroinflammatory and neurodegenerative disease, by activating microglia which in turn kill oligodendrocytes.

【 授权许可】

   
2012 Yeo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Wekerle H: Lessons from multiple sclerosis: models, concepts, observations. Ann Rheum Dis 2008, Suppl 3:iii56-iii60.
• [2]Baker D, Gerritsen W, Rundle J, Amor S: Critical appraisal of animal models of multiple sclerosis. Mult Scler 2011, 17:647-657.
• [3]Lee SW, Croft M: 4-1BB as a therapeutic target for human disease. Adv Exp Med Biol 2009, 647:120-129.
• [4]Wang C, Lin GH, McPherson AJ, Watts TH: Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev 2009, 229:192-215.
• [5]Thum E, Shao Z, Schwarz H: CD137, implications in immunity and potential for therapy. Front Biosci 2009, S1:336-351.
• [6]Tamada K, Chen L: Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules. Cancer Immunol Immunother 2006, 55:355-362.
• [7]Eissner G, Kolch W, Scheurich P: Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev 2004, 15:353-366.
• [8]Shao Z, Schwarz H: CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction. J Leukoc Biol 2011, 89:21-29.
• [9]Langstein J, Michel J, Fritsche J, Kreutz M, Andreesen R, Schwarz H: CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling. J Immunol 1998, 160:2488-2494.
• [10]Langstein J, Becke FM, Sollner L, Krause G, Brockhoff G, Kreutz M, Andreesen R, Schwarz H: Comparative analysis of CD137 and LPS effects on monocyte activation, survival, and proliferation. Biochem Biophys Res Commun 2000, 273:117-122.
• [11]Langstein J, Schwarz H: Identification of CD137 as a potent monocyte survival factor. J Leukoc Biol 1999, 65:829-833.
• [12]Langstein J, Michel J, Schwarz H: CD137 induces proliferation and endomitosis in monocytes. Blood 1999, 94:3161-3168.
• [13]Drenkard D, Becke FM, Langstein J, Spruss T, Kunz-Schughart LA, Tan TE, Lim YC, Schwarz H: CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity. FASEB J 2007, 21:456-463.
• [14]Lippert U, Zachmann K, Ferrari DM, Schwarz H, Brunner E, Latif AH, Neumann C, Soruri A: CD137 ligand reverse signaling has multiple functions in human dendritic cells during an adaptive immune response. Eur J Immunol 2008, 38:1024-1032.
• [15]Ju S, Ju S, Ge Y, Qiu H, Lu B, Qiu Y, Fu J, Liu G, Wang Q, Hu Y, Shu Y, Zhang X: A novel approach to induce human DCs from monocytes by triggering 4-1BBL reverse signaling. Int Immunol 2009, 21:1135-1144.
• [16]Kwajah MMS, Schwarz H: CD137 ligand signaling induces human monocyte to dendritic cell differentiation. Eur J Immunol 2010, 40:1938-49.
• [17]Jiang D, Yue PS, Drenkard D, Schwarz H: Induction of proliferation and monocytic differentiation of human CD34+ cells by CD137 ligand signaling. Stem Cells 2008, 26:2372-2381.
• [18]Jiang D, Chen Y, Schwarz H: CD137 induces proliferation of murine hematopoietic progenitor cells and differentiation to macrophages. J Immunol 2008, 181:3923-3932.
• [19]Prinz M, Mildner A: Microglia in the CNS: immigrants from another world. GLIA 2011, 59:177-187.
• [20]Davoust N, Vuaillat C, Androdias G, Nataf S: From bone marrow to microglia: barriers and avenues. Trends Immunol 2008, 29:227-234.
• [21]Dheen ST, Kaur C, Ling EA: Microglial activation and its implications in the brain diseases. Curr Med Chem 2007, 14:1189-1197.
• [22]Gay F: Activated microglia in primary MS lesions: defenders or aggressors? Int MS J 2007, 14:78-83.
• [23]Li J, Ramenaden ER, Peng J, Koito H, Volpe JJ, Rosenberg PA: Tumor necrosis factor alpha mediates lipopolysaccharide-induced microglial toxicity to developing oligodendrocytes when astrocytes are present. J Neurosci 2008, 28:5321-5330.
• [24]Kwajah MMS, Mustafa N, Holme AL, Pervaiz S, Schwarz H: Biphasic activity of CD137 ligand-stimulated monocytes on T cell apoptosis and proliferation. J Leukoc Biol 2011, 89:707-720.
• [25]Tang Q, Jiang D, Shao Z, Martinez Gomez JM, Schwarz H: Species Difference of CD137 Ligand Signaling in Human and Murine Monocytes. PLoS One 2011, 6:e16129.
• [26]Sun Y, Lin X, Chen HM, Wu Q, Subudhi SK, Chen L, Fu YX: Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol 2002, 168:1457-1465.
• [27]Kim YH, Choi BK, Shin SM, Kim CH, Oh HS, Park SH, Lee DG, Lee MJ, Kim KH, Vinay DS, Kwon BS: 4-1BB triggering ameliorates experimental autoimmune encephalomyelitis by modulating the balance between Th17 and regulatory T cells. J Immunol 2011, 187:1120-1128.
• [28]Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L: Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997, 3:682-685.
• [29]Foell JL, Ez-Mendiondo BI, Diez OH, Holzer U, Ruck P, Bapat AS, Hoffmann MK, Mittler RS, Dannecker GE: Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance. Immunology 2004, 113:89-98.
• [30]Kim J, Choi WS, La S, Suh JH, Kim BS, Cho HR, Kwon BS, Kwon B: Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells. Blood 2005, 105:2206-2213.
• [31]Blazar BR, Kwon BS, Panoskaltsis-Mortari A, Kwak KB, Peschon J, Taylor PA: Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J Immunol 2001, 166:3174-3183.
• [32]Curto M, Reali C, Palmieri G, Scintu F, Schivo ML, Sogos V, Marcialis MA, Ennas MG, Schwarz H, Pozzi G, Gremo F: Inhibition of cytokines expression in human microglia infected by virulent and non-virulent mycobacteria. Neurochem Int 2004, 44:381-392.